Viatris Inc (VTRS) stock

VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 6/309% below fair value

$19.04−0.16 (-0.86%)

Close on Oct 30, 2026Market cap $21.86BP/E –Yield 2.52%

Earnings

Viatris's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Nov 5, 2026

Q3 FY2026 · estimated, before the open

Revenue, Q2 FY2026

$3.80B

Adjusted EPS, Q2 FY2026

$0.69

Latest guidance

Raised

Aug 6, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of Viatris's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q3 FY2026ended Sep 30, 2026	Nov 5, 2026Expected	–	–	–	–	–
Q2 FY2026ended Jun 30, 2026	Aug 6, 2026before the open	$3.80B	–	-$0.10	$0.69	Release
Q1 FY2026ended Mar 31, 2026	May 7, 2026before the open	$3.52B	+8.1%	$0.15	$0.59	Release
Q4 FY2025ended Dec 31, 2025	Feb 26, 2026before the open	$3.70B	+4.9%	-$0.30	$0.57	Release
Q3 FY2025ended Sep 30, 2025	Nov 6, 2025before the open	$3.76B	+0.2%	-$0.11	$0.67	Release
Q2 FY2025ended Jun 30, 2025	Aug 7, 2025before the open	–	–	–	–	Release
Q1 FY2025ended Mar 31, 2025	May 8, 2025before the open	$3.25B	-11.1%	-$2.55	$0.50	Release
Q4 FY2024ended Dec 31, 2024	Feb 27, 2025before the open	$3.53B	-8.1%	-$0.43	$0.54	Release
Q3 FY2024ended Sep 30, 2024	Nov 7, 2024before the open	$3.75B	-4.8%	$0.08	$0.75	Release
Q2 FY2024ended Jun 30, 2024	Aug 8, 2024before the open	$3.80B	-3.0%	-$0.27	$0.69	Release
Q1 FY2024ended Mar 31, 2024	May 9, 2024before the open	$3.66B	-1.9%	$0.09	$0.67	Release
Q4 FY2023ended Dec 31, 2023	Feb 28, 2024before the open	$3.84B	-1.0%	-$0.64	–	Release
Q3 FY2023ended Sep 30, 2023	Nov 7, 2023after the close	$3.94B	-3.4%	$0.27	–	Release
Q2 FY2023ended Jun 30, 2023	Aug 7, 2023before the open	$3.92B	-4.9%	$0.22	–	Release
Q1 FY2023ended Mar 31, 2023	May 8, 2023before the open	$3.73B	-11.0%	$0.19	–	Release
Q4 FY2022ended Dec 31, 2022	Feb 27, 2023before the open	$3.88B	-10.7%	$0.83	–	Release
Q3 FY2022ended Sep 30, 2022	Nov 7, 2022before the open	$4.08B	–	$0.29	–	Release
Q2 FY2022ended Jun 30, 2022	Aug 8, 2022before the open	$4.12B	-10.0%	$0.26	–	Release
Q1 FY2022ended Mar 31, 2022	May 9, 2022before the open	$4.19B	–	$0.33	–	Release
Q4 FY2021ended Dec 31, 2021	Feb 28, 2022before the open	$4.34B	–	-$0.22	–	Release
Q2 FY2021ended Jun 30, 2021	Aug 9, 2021before the open	$4.58B	–	-$0.23	–	Release
Q1 FY2021ended Mar 31, 2021	May 10, 2021before the open	–	–	–	–	Release
Q4 FY2020ended Dec 31, 2020	Feb 22, 2021before the open	–	–	–	–	Filing
Q1 FY2020ended Mar 31, 2020	May 29, 2020after the close	–	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Viatris's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
Total RevenuesGAAP	FY2026	$14.55B – $14.95B	–	New	Aug 6, 2026
Total Revenues	FY2026	$14.45B – $14.95B	$450.00M – $550.00M	Reaffirmed	May 7, 2026
Adjusted EBITDAnon-GAAP	FY2026	$4.30B – $4.50B	$4.15B – $4.45B	Raised	Aug 6, 2026
Adjusted EPSnon-GAAP	FY2026	$2.45 – $2.59	$2.33 – $2.47	Raised	Aug 6, 2026
Free Cash Flow Excluding Transaction-related and Restructuring-related Costsnon-GAAP	FY2026	$2.05B – $2.35B	$1.95B – $2.35B	Raised	Aug 6, 2026
Capital Expenditures	FY2026	$350.00M – $450.00M	$350.00M – $450.00M	Reaffirmed	May 7, 2026
Estimated U.S. GAAP Net Cash provided by Operating ActivitiesGAAP	FY2026	$1.70B – $2.00B	–	Reaffirmed	Feb 26, 2026
U.S. GAAP net cash provided by operating activitiesGAAP	FY2026	$1.90B – $2.10B	$1.70B – $2.00B	Raised	Aug 6, 2026

Guidance history

Every forecast Viatris put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Aug 6, 2026	Adjusted EBITDA	FY2026	$4.30B – $4.50B	Raised
Aug 6, 2026	Adjusted EPS	FY2026	$2.45 – $2.59	Raised
Aug 6, 2026	Free Cash Flow Excluding Transaction-related and Restructuring-related Costs	FY2026	$2.05B – $2.35B	Raised
Aug 6, 2026	U.S. GAAP net cash provided by operating activities	FY2026	$1.90B – $2.10B	Raised
Aug 6, 2026	Total Revenues	FY2026	$14.55B – $14.95B	New
May 7, 2026	Capital Expenditures	FY2026	$350.00M – $450.00M	Reaffirmed
May 7, 2026	Adjusted EBITDA	FY2026	$4.15B – $4.45B	Reaffirmed
May 7, 2026	Adjusted EPS	FY2026	$2.33 – $2.47	Reaffirmed
May 7, 2026	Free Cash Flow Excluding Transaction-related and Restructuring-related Costs	FY2026	$1.95B – $2.35B	Raised
May 7, 2026	Free Cash Flow	FY2026	$1.25B – $1.65B	Lowered
May 7, 2026	U.S. GAAP net cash provided by operating activities	FY2026	$1.70B – $2.00B	Reaffirmed
May 7, 2026	Total Revenues	FY2026	$14.45B – $14.95B	Reaffirmed
May 7, 2026	new product revenues	FY2026	$450.00M – $550.00M	Lowered
Feb 26, 2026	Capital Expenditures	FY2026	$350.00M – $450.00M	New
Feb 26, 2026	Adjusted EBITDA	FY2026	$4.15B – $4.45B	New
Feb 26, 2026	Adjusted EPS	FY2026	$2.33 – $2.47	New
Feb 26, 2026	Free Cash Flow Excluding Transaction-related and Restructuring-related Costs	FY2026	$1.95B – $2.35B	New
Feb 26, 2026	Free Cash Flow	FY2026	$1.25B – $1.65B	Lowered
Feb 26, 2026	U.S. GAAP net cash provided by operating activities	FY2026	$1.70B – $2.00B	New
Feb 26, 2026	Estimated U.S. GAAP Net Cash provided by Operating Activities	FY2026	$1.70B – $2.00B	Reaffirmed
Feb 26, 2026	new product revenues	FY2026	$450.00M – $550.00M	New
Feb 26, 2026	Total Revenues	FY2026	$14.45B – $14.95B	Raised
Nov 6, 2025	Capital Expenditures	FY2025	$300.00M – $350.00M	New
Nov 6, 2025	Adjusted EBITDA	FY2025	$4.00B – $4.20B	New
Nov 6, 2025	Adjusted EPS	FY2025	$2.25 – $2.35	New
Nov 6, 2025	Free Cash Flow	FY2025	$1.85B – $2.15B	New
Nov 6, 2025	U.S. GAAP net cash provided by operating activities	FY2025	$2.20B – $2.45B	Lowered
Nov 6, 2025	Total Revenues	FY2025	$13.90B – $14.30B	New
Aug 7, 2025	total share repurchases	FY2025	$500.00M – $650.00M	New
Aug 7, 2025	U.S. GAAP net cash provided by operating activities	FY2025	$2.20B – $2.50B	New
May 8, 2025	Capital Expenditures	FY2025	$300.00M – $400.00M	Reaffirmed
May 8, 2025	Adjusted EBITDA	FY2025	$3.89B – $4.19B	Lowered
May 8, 2025	Adjusted EPS	FY2025	$2.16 – $2.30	Raised
May 8, 2025	Free Cash Flow	FY2025	$1.80B – $2.20B	Reaffirmed
May 8, 2025	U.S. GAAP net cash provided by operating activities	FY2025	$2.20B – $2.50B	New
May 8, 2025	Total Revenues	FY2025	$13.50B – $14.00B	Reaffirmed
Feb 27, 2025	Capital Expenditures	FY2025	$300.00M – $400.00M	New
Feb 27, 2025	Adjusted EBITDA	FY2025	$3.90B – $4.20B	New
Feb 27, 2025	Adjusted EPS	FY2025	$2.12 – $2.26	New
Feb 27, 2025	Free Cash Flow	FY2025	$1.80B – $2.20B	New
Feb 27, 2025	new product revenues	FY2025	$450.00M – $550.00M	New
Feb 27, 2025	Total Revenues	FY2025	$13.50B – $14.00B	Raised
Nov 7, 2024	Capital Expenditures	FY2024	$350.00M – $450.00M	New
Nov 7, 2024	Free Cash Flow	FY2024	$2.17B – $2.57B	Reaffirmed
Nov 7, 2024	U.S. GAAP net cash provided by operating activities	FY2024	$2.62B – $2.92B	Reaffirmed
Nov 7, 2024	revenue growth	FY2024	+2%	New
Nov 7, 2024	Total Revenues	FY2024	$14.60B – $15.10B	Lowered
Nov 7, 2024	new product revenues	FY2024	$500.00M – $600.00M	Lowered
Aug 8, 2024	Capital Expenditures	FY2024	$350.00M – $450.00M	New
Aug 8, 2024	Adjusted EBITDA	FY2024	$4.60B – $4.87B	Lowered
Aug 8, 2024	Adjusted EPS	FY2024	$2.58 – $2.73	Lowered
Aug 8, 2024	Free Cash Flow	FY2024	$2.17B – $2.57B	Lowered
Aug 8, 2024	New Product Revenues	FY2024	$500.00M – $600.00M	New
Aug 8, 2024	U.S. GAAP net cash provided by operating activities	FY2024	$2.62B – $2.92B	Lowered
Aug 8, 2024	Total Revenues Growth	FY2024	+2%	New
Aug 8, 2024	U.S. GAAP total revenues	FY2024	$14.60B – $15.10B	New
May 9, 2024	Adjusted EBITDA	FY2024	$4.71B – $5.01B	Lowered
May 9, 2024	Adjusted EPS	FY2024	$2.66 – $2.81	Lowered
May 9, 2024	Free Cash Flow	FY2024	$2.26B – $2.66B	Lowered
May 9, 2024	Total Revenues	FY2024	$14.98B – $15.48B	Lowered
Feb 28, 2024	Adjusted EBITDA	FY2024	$4.80B – $5.10B	New
Feb 28, 2024	Adjusted EPS	FY2024	$2.70 – $2.85	New
Feb 28, 2024	Free Cash Flow	FY2024	$2.30B – $2.70B	New
Feb 28, 2024	U.S. GAAP net cash provided by operating activities	FY2024	$2.75B – $3.05B	New
Feb 28, 2024	Total Revenues	FY2024	$15.25B – $15.75B	New
Nov 7, 2023	Capital Expenditures	FY2023	$400.00M – $500.00M	Reaffirmed
Nov 7, 2023	Free Cash Flow	FY2023	$2.30B – $2.70B	Reaffirmed
Nov 7, 2023	adjusted gross margin	FY2023	58.5% – 59%	New
Nov 7, 2023	U.S. GAAP net cash provided by operating activities	FY2023	$2.80B – $3.10B	Reaffirmed
Aug 7, 2023	Adjusted EBITDA	FY2023	$5.00B – $5.40B	Reaffirmed
Aug 7, 2023	Free Cash Flow	FY2023	$2.30B – $2.70B	Reaffirmed
Aug 7, 2023	Total Revenues	FY2023	$15.50B – $16.00B	Reaffirmed
May 8, 2023	Capital Expenditures	FY2023	$400.00M – $500.00M	New
May 8, 2023	Adjusted EBITDA	FY2023	$5.00B – $5.40B	Reaffirmed
May 8, 2023	Free Cash Flow	FY2023	$2.30B – $2.70B	Reaffirmed
May 8, 2023	U.S. GAAP net cash provided by operating activities	FY2023	$2.80B – $3.10B	Reaffirmed
May 8, 2023	Total Revenues	FY2023	$15.50B – $16.00B	New
Feb 27, 2023	Capital Expenditures	FY2023	$400.00M – $500.00M	New
Feb 27, 2023	Adjusted EBITDA	FY2023	$5.00B – $5.40B	New
Feb 27, 2023	Free Cash Flow	FY2023	$2.30B – $2.70B	New
Feb 27, 2023	U.S. GAAP net cash provided by operating activities	FY2023	$2.80B – $3.10B	New
Feb 27, 2023	Total Revenues	FY2023	$15.50B – $16.00B	New
Nov 7, 2022	Adjusted EBITDA	FY2022	$5.80B – $6.20B	Reaffirmed
Nov 7, 2022	Free Cash Flow	FY2022	$2.50B – $2.90B	Reaffirmed
Nov 7, 2022	Total Revenues	FY2022	$16.20B – $16.70B	Lowered
Aug 8, 2022	Capital Expenditures	FY2022	$425.00M – $575.00M	New
Aug 8, 2022	Free Cash Flow	FY2022	$2.50B – $2.90B	Reaffirmed
Aug 8, 2022	U.S. GAAP net cash provided by operating activities	FY2022	$3.10B – $3.30B	Lowered
May 9, 2022	Capital Expenditures	FY2022	$525.00M – $675.00M	Reaffirmed
May 9, 2022	Adjusted EBITDA	FY2022	$5.80B – $6.20B	Reaffirmed
May 9, 2022	Free Cash Flow	FY2022	$2.50B – $2.90B	Reaffirmed
May 9, 2022	U.S. GAAP net cash provided by operating activities	FY2022	$3.20B – $3.40B	Reaffirmed
May 9, 2022	Total Revenues	FY2022	$17.00B – $17.50B	Reaffirmed
Feb 28, 2022	Capital Expenditures	FY2022	$525.00M – $675.00M	New
Feb 28, 2022	Adjusted EBITDA	FY2022	$5.80B – $6.20B	New
Feb 28, 2022	Free Cash Flow	FY2022	$2.50B – $2.90B	New
Feb 28, 2022	U.S. GAAP net cash provided by operating activities	FY2022	$3.20B – $3.40B	New
Feb 28, 2022	Total Revenues	FY2022	$17.00B – $17.50B	New
Aug 9, 2021	Adjusted EBITDA	FY2021	$6.15B – $6.45B	New
Aug 9, 2021	Free Cash Flow	FY2021	$2.20B – $2.40B	New
Aug 9, 2021	Total Revenues	FY2021	$17.50B – $17.90B	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.